2.3.1.17: aspartate N-acetyltransferase

This is an abbreviated version!
For detailed information about aspartate N-acetyltransferase, go to the full flat file.

Reaction

Synonyms

acetyltransferase, aspartate, ANAT, aspartate acetyltransferase, aspartate N-acetyltransferase, aspartic acetylase, L-aspartate N-acetyltransferase, NAT, NAT8L

ECTree

     2 Transferases

         2.3 Acyltransferases

             2.3.1 Transferring groups other than aminoacyl groups

                2.3.1.17 aspartate N-acetyltransferase

Advanced search results

Do not include text mining results

Include results (more...)

Include results (more...)

Results	in table
1	Activating Compound
16	AA Sequence
1	Application
1	CAS Registry Number
6	Cloned(Commentary)
3	Crystallization (Commentary)
45	Disease/ Diagnostics
2	General Information
2	IC50 Value
55	Inhibitors
24	Ki Value [mM]
30	KM Value [mM]
11	Localization
10	Metals/Ions
2	Molecular Weight [Da]
7	Natural Substrates/ Products (Substrates)
17	Organism
2	Pathway
3	pH Optimum
3	pH Range
15	Protein Variants
7	Purification (Commentary)
1	Reaction
1	Reaction Type
17	Reference
25	Source Tissue
6	Specific Activity [micromol/min/mg]
1	Storage Stability
24	Substrates and Products (Substrate)
4	Subunits
19	Synonyms
1	Systematic Name
3	Temperature Optimum [°C]
1	Temperature Stability [°C]
5	Turnover Number [1/s]

Application

print visible entries

print all entries

Go back to the abbreviated version
of the Enzyme Summary Page.

Application on EC 2.3.1.17 - aspartate N-acetyltransferase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.

top print hide show all columns Go to Application Search

Please wait a moment until the data is sorted. This message will disappear when the data is sorted.

APPLICATION

ORGANISM

UNIPROT

COMMENTARY

LITERATURE

medicine

Homo sapiens

Q8N9F0

patients with high levels of tumoral N-acetyl-L-aspartate and its biosynthetic enzyme, aspartate N-acetyltransferase (NAT8L), have worse overall survival than patients with low levels of N-acetyl-L-aspartate and NAT8L. The overall survival duration of patients with higher-than-median N-acetyl-L-aspartate levels (3.6 years) is lower than that of patients with lower-than-median N-acetyl-L-aspartate levels (5.1 years). High NAT8L gene expression in other cancers (melanoma, renal cell, breast, colon, and uterine cancers) is associated with worse overall survival. NAT8L silencing reduces cancer cell viability and proliferation. In orthotopic mouse models (ovarian cancer and melanoma), NAT8L silencing reduces tumor growth statistically significantly

757461